An Open-label, Randomised, Multicentre, Multi-country Three-arm Study of the Treatment with Finafloxacin 400 mg b.i.d. plus Esomeprazole 40 mg b.i.d. for 14 days versus Finafloxacin 400 mg b.i.d. plus Esomeprazole 40 mg b.i.d. plus Amoxicillin 1000 mg b.i.d. for 10 days versus Clarithromycin 500 mg b.i.d. plus Amoxicillin 1000 mg b.i.d. plus Esomeprazole 40 mg b.i.d. for 10 Days in Patients with Helicobacter pylori infection. Finafloxacin in patients with Helicobacter: The FLASH 2 Study - FLASH 2 Study

MerLion Pharmaceuticals GmbH0 个研究点目标入组 360 人开始时间: 2009年7月1日最近更新: 2012年4月24日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: MerLion Pharmaceuticals GmbH
入组人数: 360

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Male or female subjects of 18 to 70 years old.
•2. Presence of dyspepsia or dyspeptic symptoms.
•3. Able to understand the nature of the study and provide written informed consent.
•4. Able to communicate with study personnel.
•5. Gastroscopic confirmation of H. pylori infection by Rapid Urease Tests.
•6. Positive Urea Breath Test.
•7. Absence of blood in stools.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Gastroscopic confirmation of gastric and/or duodenal ulcers.
•2. History of Zollinger-Ellison syndrome.
•3. Gastroesophageal Reflux Disease (GERD) with Los Angeles classification grade C or D (Appendix 1).
•4. Subtotal gastrectomy or vagotomy in medical history.
•5. Pyloric stenosis.
•6. Previous H. pylori eradication therapy.
•7. Likely to require one of the following medications within two weeks prior to or during the study period:
•any other antibiotic than the study medication;
•any other proton-pump inhibitor than the study medication;
•antacids (only forbidden during the medication phase);
•H2 blockers.
•8. Bismuth compounds used within four weeks prior to, or during, the study period.
•9. Psychiatric, neurological or behavioural disorders that may interfere with the conduct or interpretation of the study.
•10. Severe concomitant disease of the cardiovascular, pulmonary, hepatic, renal, haematological, lymphatic, metabolic or endocrine system (controlled diabetes is allowed).
•11. Clinically relevant serious unstable physical illness: treated, controlled and thus stable hypertension is not considered an exclusion criterion.
•12. Known uncontrolled hypertension or symptomatic hypotension.
•13. Subjects who are immunocompromised.
•14. Malignant disease of any kind except basalioma.
•15. Clinically relevant abnormal vital signs.
•16. Clinically relevant abnormal ECG findings.
•17. Clinically relevant abnormal laboratory data at screening, or any abnormal laboratory value that could interfere with the assessment of safety.
•18. Exposure to any investigational drug within 30 days prior Screening.
•19. Known hypersensitivity or other contraindication to the use of fluoroquinolones and other study medication.
•20. Prior participation in finafloxacin studies.
•21. Pregnant or nursing women. Women of childbearing potential must use effective contraception during the study, e.g. oral (stable doses for at least three months prior to screening) or injectable (stable doses for at least two months prior to screening) contraceptives, implanted levonorgestrel contraceptives, intrauterine devices (for at least two months prior to screening) and/or barrier methods (combination of diaphragm and spermicide, or condom and spermicide), sexual abstinence or vasectomised partner.
•22. Current diagnosis or known history of substance abuse.
•23. Site personnel and their immediate families; defined as their spouse, parent, child, grandparent or grandchild.
•24. Reasonable likelihood for non-compliance with the protocol or any other reason that, in the investigator’s opinion, prohibits the inclusion of the subject into the study.

研究者

发起方

MerLion Pharmaceuticals GmbH

相似试验

进行中（未招募）

不适用

An Open-label, Randomised, Multicentre, Multi-country Three-arm Study of the Treatment with Finafloxacin 400 mg b.i.d. plus Esomeprazole 40 mg b.i.d. for 14 days versus Finafloxacin 400 mg b.i.d. plus Esomeprazole 40 mg b.i.d. plus Amoxicillin 1000 mg b.i.d. for 10 days versus Clarithromycin 500 mg b.i.d. plus Amoxicillin 1000 mg b.i.d. plus Esomeprazole 40 mg b.i.d. for 10 Days in Patients with Helicobacter pylori infection. Finafloxacin in patients with Helicobacter: The FLASH 2 Study - FLASH 2 StudyMedDRA version: 9.1Level: LLTClassification code 10019377Term: Helicobacter pylori infectionHelicobacter pylori infection

EUCTR2009-011865-10-PLMerLion Pharmaceuticals GmbH360

进行中（未招募）

不适用

EUCTR2009-011865-10-DEMerLion Pharmaceuticals GmbH360

进行中（未招募）

不适用

EUCTR2009-011865-10-LVMerLion Pharmaceuticals GmbH360

进行中（未招募）

不适用

A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.

EUCTR2014-004693-42-NLIntercept Pharmaceuticals, Inc.60

已完成

1 期

Pharmacokinetic study of two formulations of paliperidone palmitate extended-release injectable suspension in patients with schizophrenia.

CTRI/2018/05/013703Mylan Laboratories Limited267